To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Brielle Urciuoli
PARP inhibitors have drastically changed the treatment landscape – and outcomes – of patients with ovarian cancer. However, despite promise shown among this class of drugs, it is still unclear which agent is the best to use in the maintenance setting.
Khevin Barnes
My wife died on Valentine's Day, and I never thought that the holiday would be the same again.
Kristinna Abalos
If your chair was cold, I knew you were two floors down in the NICU cradling your only child – the only one I’d be able to give you – making sure his IV and nutrition lines were also connected and beeping lively and skipping at the same beat as mine.
Brielle Urciuoli
Overall survival should not be the sole factor in determining whether a drug gets approved, according to Maurie Markman, M.D.
Kristie L. Kahl
As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer Institute.
Brielle Urciuoli
“Obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state,” the authors wrote. “However, it’s unclear how this would play out in the era of immunotherapy, where inflammation has been linked to treatment response.”
Kristie L. Kahl
“Adding HIPEC to interval debulking improved both recurrence free survival and overall survival without increasing morbidity,” said van Driel.
Kristie L. Kahl
As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.
Kristie L. Kahl
Even when a patient thinks they may have exhausted their very last treatment option, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study is just the thing they may need.
Kelly Irvin
Some patients refer to this as their cancerversary. With two years in the rear-view mirror, I’m calling it my Everything-From-Here-On-Out-Is-Gravy Day.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable